查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947906

罕見疾病個人化治療解決方案市場分析及預測（至2035年）：按類型、產品、服務、技術、適應症、最終用戶、部署類型、設備和解決方案分類

Personalized Treatment Solutions for Rare Diseases Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Deployment, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 364 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

罕見疾病個人化治療方案市場預計將從2024年的6.722億美元成長到2034年的17.575億美元，複合年成長率約為11.5%。該市場涵蓋針對罕見疾病患者獨特的基因和分子特徵而設計的客製化治療方案。它整合了先進的基因組學、生物技術和數據分析技術，以開發個人化治療方法。公眾意識的提高和技術的進步正在推動市場成長，精準醫療和以病人為中心的照護是其發展的關鍵。包括製藥公司和研究機構在內的相關人員之間的合作對於克服挑戰、釋放這一小眾但極具影響力的領域的潛力至關重要。

受基因組學和生物技術進步的推動，針對罕見疾病的個人化治療方案市場正經歷強勁成長。基因治療細分市場表現最為突出，可望透過標靶基因修飾實現根治性治療。緊隨其後的是細胞療法，它利用幹細胞技術的進步來應對罕見疾病的病理。精準醫療以其個人化治療方案為特徵，在診斷能力提升和個人化藥物研發的推動下，正蓬勃發展。人工智慧和機器學習在數據分析中的應用正在革新患者個人化治療方案，確保更高的療效和更低的副作用。生物製藥領域，包括單株抗體和重組蛋白，已成為第二大成長領域，這得益於其能夠解決複雜的疾病機制。針對弱勢患者群體設計的孤兒藥，由於有利的監管激勵措施，持續吸引大量投資。製藥公司與研究機構之間的合作至關重要，它能夠加速創新，並為罕見疾病患者拓展治療選擇。

市場區隔
類型 基因療法、細胞療法、藥物基因體學、單株抗體、RNA治療方法、酵素替代療法
產品 生物製藥、小分子化合物、診斷試劑、伴隨診斷試劑
服務 諮詢服務、遺傳諮詢、檢測服務、臨床試驗、法規遵循、病患支援服務
科技 CRISPR、次世代定序、奈米技術、蛋白質體學、生物資訊學
應用領域 腫瘤科、神經科、心臟科、代謝性疾病科、免疫科、血液科
最終用戶 醫院、專科診所、研究機構、製藥和生技公司
實施表格 本機部署、雲端部署、混合式部署
裝置 穿戴式、植入式和診斷設備
解決方案 數據分析、病患管理、臨床決策支援、供應鏈管理

罕見疾病個人化治療方案市場的特徵是市場佔有率和定價策略的動態變化。在基因組學和生物技術進步的推動下，新產品層出不窮。各公司正利用最尖端科技提供客製化的治療方案，以改善患者的治療效果。藥物研發的複雜性和市場的特殊性往往會影響定價策略，因此需要創新的財務模式來確保藥物的可近性和可負擔性。策略夥伴關係和合作在該領域蓬勃發展，進一步推動了新型治療方案的普及。個人化治療方案市場的競爭異常激烈，主要參與者都在尋求透過創新和策略聯盟來獲得競爭優勢。基準研究表明，擁有強大研發能力和良好監管合規性的公司佔據著市場主導地位。監管的影響，尤其是在北美和歐洲，在塑造市場動態發揮關鍵作用。這些法規確保了治療方法的安全性和有效性，同時創造了一個鼓勵創新的環境。在市場認知度不斷提高、技術進步和有利的法規結構的推動下，該市場有望實現顯著成長。

主要趨勢和促進因素：

受多項關鍵趨勢和促進因素的影響，罕見疾病個人化治療方案市場正經歷強勁成長。其中一個顯著趨勢是基因組技術的進步，該技術能夠精準識別導致罕見疾病的基因突變。這促進了標靶治療的研發，提高了治療效果和患者預後。此外，製藥公司與研究機構之間日益密切的合作也加速了藥物發現和研發進程。以患者為中心的理念興起也是一個顯著趨勢，醫療服務提供者越來越傾向於根據患者的個別情況制定個人化治療方案。這一轉變源於對個人化醫療解決方案日益成長的需求以及病人參與的提高。政府對罕見疾病藥物的監管支持也是一個關鍵促進因素，各國政府提供激勵措施以加速治療方法的研發。此外，人工智慧和機器學習等技術創新正在透過實現預測分析和個人化治療方案，改變醫療保健格局。遠端醫療和數位健康平台的擴展進一步促進了個人化醫療的普及，尤其是在偏遠地區。總而言之，這些趨勢和促進因素共同支撐著市場持續成長和創新的潛力。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 基因治療
    • 細胞療法
    • 藥物基因組學
    • 單株抗體
    • 基於RNA的治療方法
    • 酵素替代療法
  • 市場規模及預測：依產品分類
    • 生物製藥
    • 低分子化合物
    • 診斷試劑
    • 伴隨診斷
  • 市場規模及預測：依服務分類
    • 體檢服務
    • 遺傳諮詢
    • 檢查服務
    • 臨床試驗
    • 監理合規
    • 病人支援服務
  • 市場規模及預測：依技術分類
    • CRISPR
    • 次世代定序
    • 奈米科技
    • 蛋白質體學
    • 生物資訊學
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 神經病學
    • 心臟病學
    • 代謝性疾病
    • 免疫學
    • 血液學
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
    • 製藥公司
    • 生技公司
  • 市場規模及預測：依實施類型分類
    • 本地部署
    • 基於雲端的
    • 混合
  • 市場規模及預測：依設備分類
    • 穿戴式裝置
    • 植入式裝置
    • 診斷設備
  • 市場規模及預測：按解決方案分類
    • 數據分析
    • 病患管理
    • 臨床決策支持
    • 供應鏈管理

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Bio Marin Pharmaceutical
  • Ultragenyx Pharmaceutical
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • PTC Therapeutics
  • Alexion Pharmaceuticals
  • Horizon Therapeutics
  • uni Qure
  • Orchard Therapeutics
  • REGENXBIO
  • Rocket Pharmaceuticals
  • Amicus Therapeutics
  • Krystal Biotech
  • Audentes Therapeutics
  • Gen Sight Biologics
  • Sangamo Therapeutics
  • AVROBIO
  • Pro QR Therapeutics
  • Axovant Gene Therapies

第9章：關於我們

簡介目錄
Product Code: GIS32943

Personalized Treatment Solutions for Rare Diseases Market is anticipated to expand from $672.2 million in 2024 to $1,757.5 million by 2034, growing at a CAGR of approximately 11.5%. The Personalized Treatment Solutions for Rare Diseases Market encompasses tailored therapeutic approaches designed to address the unique genetic and molecular profiles of individual patients with rare conditions. This market integrates advanced genomics, biotechnology, and data analytics to develop customized interventions. Increasing awareness and technological advancements are propelling growth, with a focus on precision medicine and patient-centric care. Collaboration among stakeholders, including pharmaceutical companies and research institutions, is crucial to overcoming challenges and unlocking potential in this niche yet impactful sector.

The Personalized Treatment Solutions for Rare Diseases Market is experiencing robust growth, fueled by advancements in genomics and biotechnology. The gene therapy sub-segment is the top performer, offering promising potential for curative treatments through targeted genetic modifications. Cell therapy follows, leveraging stem cell advancements to address rare disease pathologies. Precision medicine, characterized by its tailored approach, is gaining momentum, driven by enhanced diagnostic capabilities and personalized drug development. The integration of AI and machine learning in data analysis is revolutionizing patient-specific treatment plans, ensuring higher efficacy and reduced adverse effects. The biologics segment, encompassing monoclonal antibodies and recombinant proteins, is emerging as the second-highest performing area. It benefits from its ability to address complex disease mechanisms. Orphan drugs, designed for small patient populations, continue to attract significant investment due to favorable regulatory incentives. Collaborative efforts between pharmaceutical companies and research institutions are pivotal, accelerating innovation and expanding therapeutic options for rare disease patients.

Market Segmentation
TypeGene Therapy, Cell Therapy, Pharmacogenomics, Monoclonal Antibodies, RNA-Based Therapies, Enzyme Replacement Therapy
ProductBiologics, Small Molecules, Diagnostics, Companion Diagnostics
ServicesConsultation Services, Genetic Counseling, Laboratory Testing, Clinical Trials, Regulatory Compliance, Patient Support Services
TechnologyCRISPR, Next-Generation Sequencing, Nanotechnology, Proteomics, Bioinformatics
ApplicationOncology, Neurology, Cardiology, Metabolic Disorders, Immunology, Hematology
End UserHospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Companies
DeploymentOn-Premise, Cloud-Based, Hybrid
DeviceWearable Devices, Implantable Devices, Diagnostic Devices
SolutionsData Analytics, Patient Management, Clinical Decision Support, Supply Chain Management

The market for personalized treatment solutions for rare diseases is characterized by a dynamic landscape of market share and pricing strategies. New product launches are frequent, driven by advancements in genomics and biotechnology. Companies are leveraging cutting-edge technologies to offer bespoke therapeutic options, enhancing patient outcomes. The pricing strategies are often influenced by the complexity of drug development and the niche nature of the market, requiring innovative financial models to ensure accessibility and affordability. This sector is witnessing a surge in strategic partnerships and collaborations, further bolstering the introduction of novel treatment solutions. Competition in the personalized treatment solutions market is intense, with key players striving for prominence through innovation and strategic alliances. Benchmarking reveals that companies with robust R&D capabilities and strong regulatory compliance are leading the charge. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics. These regulations ensure the safety and efficacy of treatments, while also fostering an environment conducive to innovation. The market is poised for significant growth, driven by increased awareness, technological advancements, and favorable regulatory frameworks.

Geographical Overview:

The personalized treatment solutions for rare diseases market is witnessing transformative growth across various regions. North America leads, driven by advanced healthcare infrastructure and increased R&D investments. The region's focus on precision medicine and supportive regulatory frameworks fosters innovation. Europe follows, supported by government initiatives and collaborations between academic institutions and biotech firms. The region's emphasis on patient-centric approaches enhances its market potential. In Asia Pacific, burgeoning healthcare expenditure and a rising prevalence of rare diseases propel the market. Countries like China and India are emerging as key players, investing in cutting-edge research and personalized medicine. Latin America and the Middle East & Africa are burgeoning markets with rising opportunities. Latin America benefits from improved healthcare access and awareness, while the Middle East & Africa are investing in healthcare advancements to address unmet needs in rare disease treatment.

The Personalized Treatment Solutions for Rare Diseases Market is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, trade tensions prompt a strategic pivot towards bolstering domestic biopharmaceutical capabilities, reducing dependency on foreign imports. China's focus on self-reliance accelerates innovation in personalized medicine, while Taiwan leverages its robust biotech infrastructure to maintain competitive advantage amidst geopolitical uncertainties. The global parent market for rare disease treatments is experiencing robust growth, spurred by technological advancements and increased R&D investments. By 2035, market evolution will hinge on strategic collaborations and resilient supply chains. Meanwhile, Middle Eastern conflicts exacerbate global supply chain vulnerabilities and elevate energy prices, indirectly affecting manufacturing and distribution costs within this sector.

Key Trends and Drivers:

The Personalized Treatment Solutions for Rare Diseases Market is experiencing robust growth due to several key trends and drivers. A significant trend is the advancement in genomic technologies, enabling precise identification of genetic mutations responsible for rare diseases. This has propelled the development of targeted therapies, enhancing treatment efficacy and patient outcomes. Furthermore, increased collaboration between pharmaceutical companies and research institutions is accelerating drug discovery and development processes. The rise of patient-centric approaches is another notable trend, with healthcare providers increasingly tailoring treatments to individual patient profiles. This shift is driven by the growing demand for personalized healthcare solutions and improved patient engagement. Regulatory support for orphan drugs is also a critical driver, with governments offering incentives to encourage the development of treatments for rare diseases. Moreover, technological innovations, such as artificial intelligence and machine learning, are transforming the landscape by enabling predictive analytics and personalized treatment plans. The expansion of telemedicine and digital health platforms is further facilitating access to personalized care, especially in remote areas. These trends and drivers collectively underscore the market's potential for sustained growth and innovation.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Gene Therapy
    • 4.1.2 Cell Therapy
    • 4.1.3 Pharmacogenomics
    • 4.1.4 Monoclonal Antibodies
    • 4.1.5 RNA-Based Therapies
    • 4.1.6 Enzyme Replacement Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Biologics
    • 4.2.2 Small Molecules
    • 4.2.3 Diagnostics
    • 4.2.4 Companion Diagnostics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation Services
    • 4.3.2 Genetic Counseling
    • 4.3.3 Laboratory Testing
    • 4.3.4 Clinical Trials
    • 4.3.5 Regulatory Compliance
    • 4.3.6 Patient Support Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 Next-Generation Sequencing
    • 4.4.3 Nanotechnology
    • 4.4.4 Proteomics
    • 4.4.5 Bioinformatics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Neurology
    • 4.5.3 Cardiology
    • 4.5.4 Metabolic Disorders
    • 4.5.5 Immunology
    • 4.5.6 Hematology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Specialty Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Companies
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 On-Premise
    • 4.7.2 Cloud-Based
    • 4.7.3 Hybrid
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Wearable Devices
    • 4.8.2 Implantable Devices
    • 4.8.3 Diagnostic Devices
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Data Analytics
    • 4.9.2 Patient Management
    • 4.9.3 Clinical Decision Support
    • 4.9.4 Supply Chain Management

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Deployment
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Deployment
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Deployment
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Deployment
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Deployment
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Deployment
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Deployment
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Deployment
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Deployment
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Deployment
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Deployment
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Deployment
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Deployment
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Deployment
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Deployment
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Deployment
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Deployment
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Deployment
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Deployment
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Deployment
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Deployment
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Deployment
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Deployment
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Deployment
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Bio Marin Pharmaceutical
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Ultragenyx Pharmaceutical
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sarepta Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Alnylam Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Ionis Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 PTC Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Alexion Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Horizon Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 uni Qure
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Orchard Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 REGENXBIO
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Rocket Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Amicus Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Krystal Biotech
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Audentes Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gen Sight Biologics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sangamo Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 AVROBIO
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Pro QR Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Axovant Gene Therapies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us